Stocks Screener

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Prothena Corporation plc

0Y3M
Current price
18.26 USD +0.9 USD (+5.16%)
Last closed 17.59 USD
ISIN USG728001086
Sector Healthcare
Industry Biotechnology
Exchange London Exchange
Capitalization 945 995 456 USD
Yield for 12 month -48.46 %
1Y
3Y
5Y
10Y
15Y
0Y3M
21.11.2021 - 28.11.2021

Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, for the treatment of Parkinson's disease and other related synucleinopathies which is in Phase IIb clinical trial; NNC6019 that is in Phase lI clinical trial for the treatment of ATTR amyloidosis; and BMS-986446 and PRX012, which is in Phase I clinical trial for the treatment of Alzheimer's disease. Its discovery and preclinical programs include PRX123, a dual Aß-Tau vaccine for the treatment and prevention of Alzheimer's disease; and PRX019 for the treatment of neurogenerative diseases, as well as TDP-43 for the treatment of amyotrophic lateral sclerosis. Prothena Corporation plc has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target a-synuclein, including prasinezumab; and a collaboration agreement with Bristol-Myers Squibb to develop and commercialize antibodies targeting tau, TDP-43. The company was incorporated in 2012 and is based in Dublin, Ireland. Address: 77 Sir John Rogerson?s Quay, Dublin, Ireland, D02 VK60

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

61.14 USD

P/E ratio

Dividend Yield

Current Year

+91 370 000 USD

Last Year

+53 905 000 USD

Current Quarter

+132 014 000 USD

Last Quarter

+50 000 USD

Current Year

+82 958 000 USD

Last Year

+53 905 000 USD

Current Quarter

+131 121 000 USD

Last Quarter

-837 000 USD

Key Figures 0Y3M

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA -90 407 000 USD
Operating Margin TTM 44.22 %
PE Ratio
Return On Assets TTM -8.36 %
PEG Ratio 0.8
Return On Equity TTM -8.75 %
Wall Street Target Price 61.14 USD
Revenue TTM 217 246 000 USD
Book Value 10.82 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY 3184.7 %
Dividend Yield
Gross Profit TTM -81 657 000 USD
Earnings per share -1.08 USD
Diluted Eps TTM -1.08 USD
Most Recent Quarter II 2024
Quarterly Earnings Growth YOY
Profit Margin -23.44 %

Dividend Analytics 0Y3M

Dividend growth over 5 years

Continuous growth

Payout Ratio 5 years average

Dividend History 0Y3M

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
Ex Dividend Date
Forward Annual Dividend Yield
Last Split Factor
Payout Ratio
Last Split Date
Dividend Date

Stock Valuation 0Y3M

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE 64.1026
Enterprise Value Revenue 1.2467
Price Sales TTM 4.3545
Enterprise Value EBITDA -3.5777
Price Book MRQ 1.414

Financials 0Y3M

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Technical indicators 0Y3M

For 52 weeks

15.3 USD 41.55 USD
50 Day MA 19.37 USD
Shares Short Prior Month 5 300 187
200 Day MA 22.93 USD
Short Ratio 10
Shares Short 6 785 191
Short Percent 19.88 %